Signature Equity Partners’s Takeda Pharmaceutical TAK Stock Holding History

Signature Equity Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.43K	Buy	401 +57	+17%	+$943	﹤0.01%	927
2026 Q1	$6.37K	Hold	344	–	–	﹤0.01%	910
2025 Q4	$5.36K	Buy	+344	New	+$4.92K	﹤0.01%	967

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Signature Equity Partners's TAK Position: Q2 2026 in Review

Signature Equity Partners increased its Takeda Pharmaceutical (TAK) stake by 17% in Q2 2026, buying an estimated $943 and bringing the position to 401 shares worth $6.43K. The position accounts for ﹤0.01% of the portfolio, ranked #927.

Signature Equity Partners first reported a position in TAK in Q4 2025 and has held it in 3 quarters since. 376 funds tracked by Wall St. Rank hold TAK as of Q2 2026.

Signature Equity Partners held 401 shares of Takeda Pharmaceutical worth $6.43K as of Q2 2026.
Signature Equity Partners bought 57 Takeda Pharmaceutical shares in Q2 2026, an estimated $943.
Takeda Pharmaceutical made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #927 holding.
Signature Equity Partners first reported a position in Takeda Pharmaceutical in Q4 2025 and has held it in 3 quarters since.
376 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.